John Daniel Hainsworth
机构：Sarah Cannon · ORCID：0000-0002-2848-6546
发表论文 789 篇 · 总被引 58353 次 · h-index 99
代表论文
- Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study (2021 · The Lancet Oncology · 被引 427)
- Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study (2022 · The Lancet Oncology · 被引 171)
- Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study (2020 · Annals of Oncology · 被引 134)
- Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study (2021 · Cancer Discovery · 被引 104)
- Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial (2019 · The Lancet Oncology · 被引 87)
- Cancer of Unknown Primary in the Molecular Era (2021 · Trends in cancer · 被引 83)